Download A new international, multicenter study has found that incretin

Suite 305
233 E. Lancaster Ave.
Ardmore, PA 19003 , Affiliate, MLHS
Office: 610-642-6800
Fax: 610-642-6850
E-mail: [email protected]
www.schwartzdiabetesdoc.com
Diabetes, Cardio-Metabolic Newsletter
Incretin Safety
2/29/16
A new international, multicenter study has found that incretin-based drugs, used to treat type 2 diabetes, are not
associated with an increased risk of pancreatic cancer. Findings from this study, published in the BMJ, might help
allay some of the concerns initially brought to the forefront by the U.S. Food and Drug Administration (FDA) in
response to increased reporting of pancreatic cancer in patients taking incretin-based drugs vs. other oral
antidiabetic agents (2.9 times higher with exenatide, 2.7 times higher with sitagliptin).
Incretin-based drugs include dipeptidyl peptidase-4 (DPP-4) inhibitors (eg, linagliptin, sitagliptin, vildagliptin,
saxagliptin) and glucagon-like peptide-1 receptor agonists (eg, exenatide, liraglutide). Previous studies which
noted the pancreatic cancer risk (but which didn't specifically investigate it) were limited in a number of ways
including, small sample sizes, low duration time follow-ups and a low number of specific incretin-based drugs. The
findings of this new study suggests that when compared to sulfonylureas, incretin-based drugs are not associated
with an increased risk of pancreatic cancer.In total, 972,384 patients from 6 participating sites in Canada, the
U.S., and the United Kingdom, were included. In follow-ups, with the median follow-up time ranging from 1.3 to
2.8 years, 1221 out of the 972,384 were newly diagnosed as having pancreatic cancer (incidence rate 0.60 per
1000 person years). Compared with use of sulfonylureas, incretin-based drugs were not associated with an
increased risk of incident pancreatic cancer (pooled adjusted hazard ratio 1.02, 95% confidence interval 0.84 to
1.23).Researchers used a nested case-control analyses methodology for each participating site. Cases of
pancreatic cancer were matched with up to 20 randomly selected controls matched on sex, age, cohort entry
data, duration of treated diabetes, and duration follow-up. Calculations on the crude incidence rate of pancreatic
cancer were based on the Poisson distribution with 95% confidence intervals.
Although incretin-based drugs have been linked with positive outcomes including lower risk of hypoglycemia,
concern has arisen that their use may increase the risk of pancreatic cancer development. In a secondary
analysis where DDP-4 and glucagon-like peptide-1 receptor agonists were stratified, the study also found no
independent association of increased risk of pancreatic cancer in the use of incretin-based drugs by class (DPP-4
inhibitors, 1.02, 0.84 to 1.24; glucagon-like peptide-1 receptor agonists, 1.13, 0.38 to 3.38).
In other secondary analyses' the results remained consistent, further disassociating the likelihood of incretinbased drugs as a cause of pancreatic cancer onset. A cumulative duration of less than one year yielded an
increased but non-significant pooled hazard ratio (1.53, 0.93 to 2.51), whereas longer durations of use generated
pooled hazard ratios close to or below unity (1-1.9 years, 1.07, 0.82 to 1.39; ≥2 years, 0.62, 0.36 to 1.07). The
analysis of time since initiation yielded pooled hazard ratios close to the null (1-1.9 years, 1.06, 0.86 to 1.31; ≥2
years, 0.93, 0.60 to 1.45). These findings were similarly observed across each class of incretin-based drug.
The patients in the study were initiated between January 2007 and June 2013, with follow-ups occurring until
June 2014, meaning the longest follow-up time was 8 years. Given the latency of the cancer, the full effects of
incretin-based drugs needs to be surveilled over longer durations in future studies. However the authors of the
study suggest their findings do provide some reassurance to patients and clinicians with concerns of an
association between incretin-based drugs and pancreatic cancer.
PATIENT’S CONCERNS RAISED BY RECENT NEWSPAPER ARTICLE CAN BE MOLLIFIED BY THIS
NEW ARTICLE- ALSO NOTE THE NEWSPAPER DID SAY FDA/NIH/ ADA DO NOT AGREE THAT
THERE IS UNDO RISK OF CANCER WITH THESE AGENTS
Feel free to call or e-mail with any questions.
I’m also happy to see any patients that need extra help.
Prior newsletters now available at
www.schwartzdiabetesdoc.com
The
information
presented,
reviewed
or discussed
personal
views and
and by no means are intended to represent or misrepresent
Please
provide
e-mail
if you
wish are
tomy
save
paper
the views of any agencies, pharmaceutical companies, product manufacturers etc. See FDA/ company literature for full prescribing
receive newsletter via e-mail.
information for any and all discussed or referenced medications or products.